The Preleukemic Syndrome (Hematopoietic Dysplasia)

  • Grover C. BagbyJr.


The morphology of the bone marrow precursors of erythrocytes, phagocytes, and platelets has been well characterized for decades. Although the molecular mechanisms driving hematopoietic cellular differentiation remain obscure, the phenotypic expression of hematopoietic cellular development is rather clear cut. In differentiation, morphologically identifiable precursor cells undergo predictable and stepwise developmental events. The linkage of these steps of differentiation with cellular replication has been recognized for many decades. That is, the process involves the production of many mature daughter cells from fewer precursor cells.


Acute Myeloid Leukemia Acute Leukemia Myelodysplastic Syndrome Refractory Anemia Clonal Evolution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Keinanen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med 1988; 318:1153–1158.PubMedCrossRefGoogle Scholar
  2. 2.
    Bagby GC. The concept of preleukemia: Clinical and laboratory studies. CRC Crit Rev Oncol Hematol 1986; 4:203–220.CrossRefGoogle Scholar
  3. 3.
    Jacobs A, Clark RE. Pathogenesis and clinical variations in the myelodysplastic syndromes. Clin Haematol 1986; 15:925–951.PubMedGoogle Scholar
  4. 4.
    Koeffler HP. Preleukaemia. Clin Haematol 1986; 15:829–850.PubMedGoogle Scholar
  5. 5.
    Hamilton-Paterson JL. Preleukemic anemia. Acta Haematol 1949; 2:309–316.PubMedCrossRefGoogle Scholar
  6. 6.
    Saarni MI, Linman JW. Preleukemia: The hematologic syndrome preceding acute leukemia. Am J Med 1973; 55:38–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Linman JW, Bagby GC. The preleukemic syndrome (hemopoietic dysplasia). Cancer 1978; 42:854–864.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobs A. Human preleukaemia: Do we have a model? Br J Cancer 1987; 55:1–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Golde DW, Cline MJ. Human preleukemia. Identification of a maturation defect in vitro. N Engl J Med 1973; 288:1083–1086.PubMedCrossRefGoogle Scholar
  10. 10.
    Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. JAMA 1953; 152:1018–1028.Google Scholar
  11. 11.
    Meacham GC, Weisberger AS. Early atypical manifestations of leukemia. Ann Intern Med 1954; 41:780–797.PubMedGoogle Scholar
  12. 12.
    Nowell PC, Besa EC, Stelmach T, Finan JB. Chromosome studies in preleukemie states. V. Prognostic significance of single versus multiple abnormalities. Cancer 1986; 58:2571–2575.PubMedCrossRefGoogle Scholar
  13. 13.
    Todd WM, Pierre RV. Preleukaemia: A long-term prospective study of 326 patients. Scand J Haematol 1986; 36 (Suppl 45):114–120.Google Scholar
  14. 14.
    Pedersen-Bjergaard J, Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: Correlation with clinical data for 61 cases. Br J Haematol 1987; 66:199–207.PubMedCrossRefGoogle Scholar
  15. 15.
    Hirai H, Kobayashi Y, Mano H, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature (London) 1987; 327:430–432.CrossRefGoogle Scholar
  16. 16.
    Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature (London) 1987; 330:186–188.CrossRefGoogle Scholar
  17. 17.
    Pauda RA, Carter G, Hughes D, et al. N-ras mutations in myelodysplasia detected by polymerase chain reaction, oligonucleotide hybridization and transformation. Blood 1987; 70:284a.Google Scholar
  18. 18.
    Liu E, Hjelle B, Morgan R, Bishop JM. The role of mutant ras genes in preleukemic states. Blood 1987; 70:282a.Google Scholar
  19. 19.
    Ibbott JW, Whitelow DM, Thomas JW. The significant percentage of blast cells in the bone marrow in the diagnosis of acute leukemia. Can Med Assoc J 1960; 82:358–361.PubMedGoogle Scholar
  20. 20.
    Bagby GC, Magenis RE. Clonal evolution in the preleukemic syndrome. In: Bagby GC, ed. The Preleukemic Syndrome (Hemopoietic Dysplasia). Boca Raton, CRC Press, 1985: pp. 127–134.Google Scholar
  21. 21.
    Broxmeyer HW, Bognacki J, Dorner MH, DeSousa M. Identification of leukemia associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med 1981; 153:1426–1444.PubMedCrossRefGoogle Scholar
  22. 22.
    Broxmeyer HE, Grossbard E, Jacobsen N, Moore MAS. Evidence for a proliferative advantage of human leukemia colony forming cells in vitro. J Natl Cancer Inst 1978; 60:497–511.PubMedGoogle Scholar
  23. 23.
    Taetle R. Acidic isoferritins (leukemia associated inhibitory activity) fail to inhibit blast proliferation in acute myelogenous leukemia. Blood 1981; 58:653–657.PubMedGoogle Scholar
  24. 24.
    Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: Heterogeneity of stem cell origin. Blood 1981; 57:1068–1073.PubMedGoogle Scholar
  25. 25.
    Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 1984; 63:1318–1323.PubMedGoogle Scholar
  26. 26.
    Jacobsen RJ, Temple MJ, Singer JW, Raskind W, Powell J, Fialkow PJ. A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipotent stem cell. Blood 1984; 310:1513–1517.Google Scholar
  27. 27.
    Heim S, Mitelman F. Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 1986; 15:1003–1021.PubMedGoogle Scholar
  28. 28.
    Tricot G, Boogaerts MA, Verwilghen RL. Treatment of patients with myelodysplastic syndromes: A review. Scand J Haematol 1986; 36 (Suppl 45):121–127.Google Scholar
  29. 29.
    Magenis RE, Yoshitomi M, Smith L, Bagby GC. Cytogenetic studies on marrow cells from patients with the preleukemic syndrome. In: Bagby GC, ed. The Preleukemic Syndrome (Hemopoietic Dysplasia). Boca Raton, CRC Press, 1985: pp. 103–126.Google Scholar
  30. 30.
    Sandberg AA. The usefulness of chromosome analysis in clinical oncology. Oncology 1987; 1:21–33.PubMedGoogle Scholar
  31. 31.
    Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60:507–516.PubMedGoogle Scholar
  32. 32.
    Huebner K, Isobe M, Croce CM, Golde DW, Kaufman SE, Gasson JC. The human gene encoding GM-CSF is at 5q21–q32, the chromosome region deleted in the 5q- anomaly. Science 1985; 230:1282–1285.PubMedCrossRefGoogle Scholar
  33. 33.
    LeBeau MM, Epstein ND, O’Brien SJ, et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sei USA 1987; 84:5913–5917.CrossRefGoogle Scholar
  34. 34.
    Yang Y-C, Kovacic S, Kriz R, et al. The human genes for GM-CSF and IL 3 are closely linked in tandem on chromosome 5. Blood 1988; 71:958–961.PubMedGoogle Scholar
  35. 35.
    Sutherland GR, Baker E, Callen DF, et al. Interleukin-5 is at 5q31 and is deleted in the 5q- syndrome. Blood 1988; 71:1150–1152.PubMedGoogle Scholar
  36. 36.
    Heim S, Billstrom R, Kristoffersson U, Mandahl N, Mitelman F. Late appearing 5q— marker in refractory anemia. Cancer Genet Cytogenet 1987; 24:159–162.PubMedCrossRefGoogle Scholar
  37. 37.
    Baer MR, Dessypris EN. Deletion of the long arm of chromosome 5 (5q—) as a secondary event in the course of refractory anemia. Cancer Genet Cytogenet 1986; 22:169–176.PubMedCrossRefGoogle Scholar
  38. 38.
    Anderson RL, Bagby GC. The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia). Leuk Res 1982; 6:175–181.PubMedCrossRefGoogle Scholar
  39. 39.
    Collins S, Coleman H, Groudine M. Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol Cell Biol 1987; 7:2870–2876.PubMedGoogle Scholar
  40. 40.
    Daley GQ, McLaughlin J, Witte ON, Baltimore D. The CML-specific p210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 1987; 237:532–535.PubMedCrossRefGoogle Scholar
  41. 41.
    Pierre RV. Cytogenetic studies in preleukemia: Studies before and after transition to acute leukemia in 17 subjects. Blood Cells 1975; 1:163–170.Google Scholar
  42. 42.
    Baker RJ, Valli VE. Dysmyelopoiesis in the cat: A hematological disorder resembling refractory anemia with excess blasts in man. Can J Vet Res 1986; 50:3–6.PubMedGoogle Scholar
  43. 43.
    Fritz TE, Tolle DV, Seed TM. The preleukemic syndrome in radiation-induced myelogenous leukemia and related myeloproliferative disorders. In: Bagby GC, ed. The Preleukemic Syndrome (Hemopoietic Dysplasia). Boca Raton, CRC Press, 1985: pp. 87–102.Google Scholar
  44. 44.
    Tolle DV, Fritz TE, Norris WP. Radiation-induced erythroleukemia in the beagle dog. Am J Pathol 1977; 87:499–510.PubMedGoogle Scholar
  45. 45.
    Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med 1982; 307:965–971.PubMedCrossRefGoogle Scholar
  46. 46.
    Anderson RL, Bagby GC. Drug-induced preleukemic syndromes. In: Bagby GC, ed. The Preleukemic Syndrome (Hemopoietic Dysplasia). Boca Raton: CRC Press, 1985: pp. 51–62.Google Scholar
  47. 47.
    Bennett JM. Classification of the myelodysplastic syndromes. Clin Haematol 1986; 15:909–1111.PubMedGoogle Scholar
  48. 48.
    Greenberg P, Bagby GC. Biologic rather than morphologic markers in myelodysplastic syndromes. Br J Haematol 1983; 53:532–533.PubMedCrossRefGoogle Scholar
  49. 49.
    Oguma S, Yoshida Y, Uchino H, Maekawa T. Varying probability of the development of acute nonlymphoblastic leukemia in refractory anemia patients with an excess of blasts. Cancer Res 1987; 47:2196–2198.PubMedGoogle Scholar
  50. 50.
    Editorial. Treatment for myelodysplastic syndromes. Lancet 1987; 2:717–719.Google Scholar
  51. 51.
    Spriggs DR, Stone RM, Kufe DW. The treatment of myelodysplastic syndromes. Clin Haematol 1986; 15:1081–1107.PubMedGoogle Scholar
  52. 52.
    Buzaid AC, Garewal HS, Greenberg BR. Management of myelodysplastic syndromes. Am J Med 1986; 80:1149–1157.PubMedCrossRefGoogle Scholar
  53. 53.
    Humphries RK, Dover G, Young NS, et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 1985; 75:547–557.PubMedCrossRefGoogle Scholar
  54. 54.
    Bagby GC, Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia). Identification of responsive patients using in vitro techniques. Ann Intern Med 1980; 92:55–58.PubMedGoogle Scholar
  55. 55.
    Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986; 63:477–483.PubMedCrossRefGoogle Scholar
  56. 56.
    Armitage JO, Dick FR, Needleman SW, Burns CP. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 1981; 65:601–605.PubMedGoogle Scholar
  57. 57.
    Baccarani M, Tura S. Differentiation of myeloid leukaemic cells: New possibilities for therapy. Br J Haematol 1979; 42:485–487.PubMedCrossRefGoogle Scholar
  58. 58.
    Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4:1857–1864.PubMedGoogle Scholar
  59. 59.
    Gold EJ, Mertelsmann RH, Itri LM, et al. Phase I clinical trial of 13-cis retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 1983; 67:981–986.PubMedGoogle Scholar
  60. 60.
    Picozzi VJ, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 1986; 4:589–595.PubMedGoogle Scholar
  61. 61.
    Kerndrup G, Bendix-Hansen K, Pedersen B, Ellegaard J, Hokland P. 13-cis retinoic acid treatment of myelodysplastic syndromes. Leuk Res 1987; 11:7–16.PubMedCrossRefGoogle Scholar
  62. 62.
    Lawrence HJ, Conner K, Kelly MA, Haussler MR, Wallace P, Bagby GC Jr. cis-Retinoic acid stimulates the clonal growth of some myeloid leukemia cells in vitro. Blood 1987; 69:302–307.PubMedGoogle Scholar
  63. 63.
    Clark RE, Jacobs A, Lush CJ, Smith SA. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1987; 1:763–765.PubMedCrossRefGoogle Scholar
  64. 64.
    Trinchieri G, Rosen M, Perussia B. Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocyte leukemic cell line HL-60. Blood 1987; 69:1218–1224.PubMedGoogle Scholar
  65. 65.
    Hemmi H, Breitman TR. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987; 69:501–507.PubMedGoogle Scholar
  66. 66.
    Elias L, Haffman R, Boswell S, Tensen L, Bonnern E. A trial of recombinant alpha-2 interferon in the myelodysplastic syndromes: I. clinical results. Leukemia 1987; 1:105–110.PubMedGoogle Scholar
  67. 67.
    Francis GE, Guimaraes JE, Berney JJ, Wing MA. Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: A new approach to differentiation induction in myelodysplasia and acute myeloid leukemia. Leuk Res 1985; 9:573–581.PubMedCrossRefGoogle Scholar
  68. 68.
    Clark RE, Ismail SAD, Jacobs A, Payne H, Smith SA. A randomised trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 1987; 66:77–83.PubMedCrossRefGoogle Scholar
  69. 69.
    Yuo A, Kitagawa S, Okabe T, et al. Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 1987; 70:404–411.PubMedGoogle Scholar
  70. 70.
    Badhan-Raj S, Keating M, LeMaistre A, et al. Stimulation of hematopoiesis in patients with myelodysplastic syndrome by recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1987; 70:144a.Google Scholar
  71. 71.
    Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblasts leukemia. Blood 1987; 69:1771–1776.PubMedGoogle Scholar
  72. 72.
    Appelbaum FR, Storb R, Ramberg RE, et al. Treatment of preleukemic syndromes with marrow transplantation. Blood 1987; 69:92–96.PubMedGoogle Scholar
  73. 73.
    O’Donnell MR, Nademanee AP, Snyder DS, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 11:1822–1826.Google Scholar
  74. 74.
    Bagby GC. The preleukemic syndrome [hematopoietic dysplasia]. Blood Rev 1988; 2:194–205.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Inc. 1990

Authors and Affiliations

  • Grover C. BagbyJr.

There are no affiliations available

Personalised recommendations